Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microtubule Associated Proteins (MAPs)01:42

Microtubule Associated Proteins (MAPs)

4.0K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
4.0K
Amyloid Fibrils03:03

Amyloid Fibrils

9.1K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Destabilization of Microtubules01:45

Destabilization of Microtubules

2.5K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can amoxicillin be detected in the aquatic environment? A critical assessment.

Environment international·2026
Same author

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders.

Cancer research·2026
Same author

Sensory deficiencies correlate with tau protein and dementia.

Frontiers in neuroscience·2026
Same author

Neuronal alkaline phosphatase promotes the spread of Tau-induced pathology, and its blockade prevents neurodegeneration and memory loss.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Performance comparison of microalgae-based and activated sludge with membrane filtration (AS-MBR) for emerging contaminant removal and wastewater reuse.

Journal of hazardous materials·2025
Same author

Structure and function of Full-length Tau.

PloS one·2025

Related Experiment Video

Updated: May 20, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.3K

Shapeshifter W-Tau Peptide Inhibits Tau Aggregation and Disintegrates Paired Helical Filaments.

Indalo Domene-Serrano1,2, Raquel Cuadros1, Vega García-Escudero1,3

  • 1Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid 28049, Spain.

Biochemistry
|March 27, 2025
PubMed
Summary

A novel W-Tau peptide inhibits tau aggregation and disrupts existing tau filaments, offering potential therapeutic benefits for neurodegenerative tauopathies like Alzheimer's disease.

More Related Videos

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

18.4K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.3K

Related Experiment Videos

Last Updated: May 20, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.3K
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

18.4K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.3K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Tauopathies are neurodegenerative diseases linked to abnormal tau protein aggregation.
  • Different tau splicing isoforms contribute to the formation of these toxic aggregates.

Purpose of the Study:

  • To investigate the role of the W-Tau peptide, derived from a novel tau isoform (W-Tau), in tau filament polymerization and depolymerization.
  • To assess the therapeutic potential of the W-Tau peptide in tauopathies.

Main Methods:

  • In silico analysis using AlphaFold3 (AF3) to predict W-Tau peptide interactions.
  • In vitro experiments to confirm W-Tau peptide's effect on tau aggregation.
  • Utilizing a FRET cell biosensor to monitor tau aggregation in the presence of W-Tau peptide and PHF seeds.
  • Analysis of PHFs from Alzheimer's disease patient samples.

Main Results:

  • The W-Tau peptide was predicted to interact with tau monomers and was confirmed to inhibit tau aggregation in vitro.
  • The W-Tau peptide effectively disrupted pre-formed paired helical filaments (PHFs) from Alzheimer's disease brains.
  • The W-Tau peptide demonstrated a decrease in tau aggregation when co-transfected with PHF seeds, confirmed by FRET biosensor.
  • W-Tau peptide breaks PHFs by unwinding them into circle-like structures.

Conclusions:

  • The W-Tau peptide shows significant potential in inhibiting and disrupting tau aggregation, suggesting therapeutic value for tauopathies.
  • The W-Tau isoform and its derived peptide represent promising candidates for future neuroprotective interventions against tauopathies.